Trials / Completed
CompletedNCT06666582
Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer
Real-world Efficacy and Toxicity Data of the Combination of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Patients With Advanced Gastric Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 185 (actual)
- Sponsor
- Hellenic Cooperative Oncology Group · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Our aim was to evaluate whether second-line treatment with paclitaxel and ramucirumab was associated with improved clinical outcomes compared to other available therapies. This study involved real-world data collection, focusing on the safety and efficacy of therapeutic combinations, administered to patients with pretreated advanced gastric cancer in the Oncology Departments affiliated with the Hellenic Cooperative Oncology Group (HeCOG).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel and ramucirumab | Second-line treatment with paclitaxel/ramucirumab vs other regimens |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2023-03-30
- Completion
- 2024-01-15
- First posted
- 2024-10-30
- Last updated
- 2024-10-30
Locations
1 site across 1 country: Greece
Source: ClinicalTrials.gov record NCT06666582. Inclusion in this directory is not an endorsement.